Skip to main content

Table 1 Clinical characteristics

From: Empirical treatment and mortality in bacteremia due to extended spectrum β-lactamase producing Enterobacterales (ESβL-E), a retrospective cross-sectional study in a tertiary referral hospital from Colombia

Variable

All patients n = 110 (%)

Survivors n = 68 (%)

Death due to sepsis n = 42 (%)

P

OR

CI95%

Age in years, median (IQR)

58 (35–73)

58 (34–73)

60 (35–73)

0.7

  

Men

69 (62)

45 (66)

24 (57)

0.3

  

Days of hospital stay, median (IQR)

26 (13–46)

32 (18–56)

21 (9–34)

0.001

  

Critical care admission

50 (45)

24 (35)

26 (61)

0.006

2.9

1.3–6.6

Ventilatory support

41 (37)

13 (19)

28 (66)

0.001

8.4

3.5–20

Days in critical care, median (IQR)

8 (3–20)

8 (4–17)

7 (1–24)

0.3

  

Serum creatinine, mg/dL, median (IQR)

0.8 (0.6–1.2)

0.8 (0.6–1.2)

0.8 (0.6–1.3)

0.3

  

Acute kidney injury

41/101 (40)

24/61 (39)

17/40 (42)

0.7

  

Serum lactate levels, mmol/L, median (IQR)

2 (1–3)

1.2 (1–3)

2 (1–2.9)

0.5

  

Lactate levels ≥ 2 mmol/L

36/70 (51)

16/37 (43)

20/33 (60)

0.1

  

Shock requiring vasopressor support

45 (40)

18 (26)

27 (64)

0.001

5

2.1–11.4

Pitt bacteremia score, median (IQR)

2 (0–4)

2 (0–2)

3 (1.7–4)

0.001

  

Pitt bacteremia score 0–1 point

43 (39)

33 (48)

10 (23)

0.01

0.3

0.1–0.7

Pitt bacteremia score > 3 points

28 (25)

9 (13)

19 (45)

0.001

5.4

2.1–13.6

qSOFA at the time sepsis is suspected, 2–3 points

41 (37)

22 (32)

19 (45)

0.1

  

Charlson comorbidity index, median (IQR)

4 (2–6)

4 (2–6)

4 (1.7–6.2)

0.9

  

Charlson > 4 points

48 (43)

29 (42)

19 (45)

0.7

  

Community acquired infection

28 (25)

19 (27)

9 (21)

0.4

  

Hospital-acquired infection

82 (74)

49 (72)

33 (78)

0.4

  

Presence of risk factors for healthcare-associated infection

84 (76)

48 (70)

36 (85)

0.07

  

Secondary bacteremia

86 (78)

53 (77)

33 (78)

0.9

  

Primary bacteremia

13 (11)

8 (11)

5 (11)

0.9

  

Catheter-associated bloodstream infection

11 (10)

7 (10)

4 (9)

0.8

  

Urinary tract infection

25/86 (29)

20/53 (37)

5/33 (15)

0.02

0.29

0.09–0.8

Source of infection other than urinary tract

61/97 (62)

33/60 (55)

28/37 (75)

0.04

2.5

1.02–6.3

Pneumonia

18/86 (20)

8/53 (15)

10/33 (30)

0.09

  

Febrile neutropenia

12/86 (14)

8/53 (15)

4/33 (12)

0.7

  

Sepsis of abdominal origin (peritonitis, cholangitis)

30/86 (34)

17/53 (32)

13/33 (39)

0.4

  

High blood pressure

53 (48)

28 (41)

25 (59)

0.06

  

Diabetes mellitus type 2

27 (24)

16 (23)

11 (26)

0.7

  

Cancer

31 (28)

19 (27)

12 (28)

0.9

  

COPD

21 (19)

12 (17)

9 (21)

0.6

  

Chronic kidney disease stage 4 and 5

19 (17)

9 (13)

10 (23)

0.1

  

Heart failure

19 (17)

12 (17)

7 (16)

0.8

  

Empirical antibiotic therapy

104 (94)

65 (95)

39 (92)

0.5

  

Total days of empirical treatment (appropriate and inappropriate)

3 (2–5)

3 (2–5)

3 (2–4)

0.5

  

Empirical treatment with carbapenem (appropriate treatment)

44/104 (42)

27/65 (41)

17/39 (43)

0.8

  

Empirical treatment with non-carbapenem antibiotics

60/104 (57)

38/65 (58)

22/39 (56)

0.8

  

Ampicillin sulbactam

12/104 (11)

8/65 (12)

4/39 (10)

1

  

Piperacillin tazobactam

29/104 (27)

18/65 (27)

11/39 (28)

0.9

  

Cefepime

14/104 (13)

10/65 (15)

4/39 (10)

0.4